Skip to content

Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients

Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07563608
Enrollment
70
Registered
2026-05-04
Start date
2018-11-10
Completion date
2026-09-01
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Brief summary

This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume overload on pulmonary pressures. Clinical follow-up is conducted at baseline and subsequently at 6, 12, and 24 months to monitor patient outcomes and standardize therapeutic management according to established European guidelines.

Interventions

None listed

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* Patients aged between 18 and 75 years * Patients on stable extracorporeal hemodialysis for at least 6 months * Dialysis frequency of two or three times per week * Ability to provide written informed consent

Exclusion criteria

* WHO functional class IV * Presence of valvular or congenital heart disease * Acute infections within the month preceding the cardiological evaluation

Design outcomes

Primary

MeasureTime frame
Prevalence of pulmonary hypertension and its subtypes in patients undergoing chronic hemodialysisBaseline (enrollment)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026